Health stocks were mixed Monday as traders received a few earnings reports but didn't see a repeat of last week's
The Nasdaq Biotechnology index was down 0.3%, while its Amex counterpart was adding 0.5%.
As for the big biotech stocks,
were down 2.4% and 3.4%, respectively.
, which last week bid for
, was losing 3.9%. Having been outdone by Gilead,
for CV Therapeutics on Monday.
Of the higher-volume movers on the Amex Biotech index,
was up 50 cents, or 4.5%, to $11.70.
Among the earnings releases,
swung to a second-quarter loss of $7.2 million, or 19 cents a share, as revenue fell and costs increased. Shares were down 5.8%, or 47 cents, but volume was light.
lost 7.3% after announcing that its fourth-quarter loss widened to roughly $10 million, or 11 cents a share, primarily due to a writedown and a charge.
rose 14.2% to $5.06 a share. The company reported on Friday that it had a fourth-quarter loss. However, a Jefferies & Co. analyst raised his rating for the stock to buy from hold after an update on two late-stage drug programs and further partnership developments.
Checking in on traditional drugmakers, the Amex Pharmaceutical index added 1.4%.
added 4.5%, and
ticked up 3.4%.
moved up 2.9%.
On the losing end,
plans to buy, gave up 2.8%. Merck lost 1.8%.